Objective: The administration of the growth hormone (GH) secretagogue GH-releasing peptide (GHRP)-2, like ghrelin, increases food intake (FI) in lean healthy men. The aim of this study was to investigate whether this effect occurs in obese subjects and whether it is dose-dependent.
Introduction
With repeated daily administration for a week, ghrelin maintains its stimulatory effect on FI; as a result, rodents increase their body fat (4, 5) .
Peripheral ghrelin administration has also been shown to stimulate FI in humans, not only in healthy lean men and women (6) , but also in patients with cancer (7) or on peritoneal dialysis (8) . Recently, ghrelin was shown to retain its stimulatory effect on FI in obese individuals (9) . We have shown recently that the administration of GH-releasing peptide (GHRP)-2 stimulates FI by 36% in healthy lean men (10) .
GHRP-2 (DAlaDβNalAlaTrpDPheLysNH 2 ), a synthetic GHS receptor agonist, belongs to a family of GHSs discovered in the 1980s and extensively studied for their effect on GH release (11) . Despite the very different chemistry of natural ghrelin and synthetic GHSs, evidence strongly and increasingly supports that they have the same biological actions (12) . Like ghrelin, GHSs increase FI (13) and body weight (14, 15) in rodents. Appetite ratings increased in children with idiopathic GH deficiency treated chronically with oral GHRP-2 (12) . The magnitude of the effect of GHRP-2 on FI in humans (10) is similar to that of ghrelin (6) .
In parallel with the data using exogenous administration of ghrelin (6) or GHRP-2 (10) , there are data suggesting that circulating ghrelin could be implicated in meal-to-meal regulation. Ghrelin levels increase in anticipation of a meal (16) and are suppressed by food ingestion (17) .
The mechanisms of these acute meal-related changes on serum ghrelin levels are multiple. The presence of nutrients in the gut (18, 19) , the calorie (20) or the carbohydrate content of the meal (21-23), vagal stimulation (24) (25) (26) , the insulin response to the meal (27, 28) , or other postgastric (pre-or post-absorptive) stimulation (28) all have been shown to play a role in mealto-meal ghrelin regulation. However, the role of the increase of insulin after a meal remains controversial (17, 29, 30) .
Serum ghrelin levels vary as a function of energy balance. Elevated ghrelin levels in patients with anorexia (31-35) decrease with weight restoration (31) . The lower levels of circulating ghrelin observed in obese individuals (36) (37) (38) (39) increase with diet-induced weight loss (40) (41) (42) . Obese individuals have less suppression of circulating ghrelin levels postprandially (43) than lean individuals (44) . Whether the dysregulation of the ghrelin system plays a part in the pathogenesis of the energy imbalance of obesity is in question.
Thus, ghrelin could be an important player not only in meal-to-meal FI behavior but also in chronic over-and undernutrition (45, 46) . Because of its dual effects on human GH (hGH) and on energy balance, ghrelin may be a critical hormonal signal of nutritional status to the somatotropic axis, playing a role in integrating energy balance with the growth process (45) .
To better understand the role of ghrelin on FI in humans, in particular whether obese individuals, who have low ghrelin levels, could respond to the exogenous administration of ghrelin, we investigated the effect of GHRP-2 at two different doses on ad libitum FI in lean and obese individuals.
Research Methods and Procedures

Study Subjects
A total of 19 subjects were studied, 10 lean (seven men and three women) and nine obese (all women). Subject characteristics are shown in Table 1 . All subjects were weight stable, healthy, not on medications, non-smoking, non-dieting, and without any eating disorder. A screening session included a full physical exam, routine laboratory tests, a taste test, and a test meal.
Subjects were asked to rate their liking of the food with a score of 5 or more (on a scale of 0 to 7) and were asked to eat at least 2090 kJ (500 kcal) during the screening test meal. No side effects were reported during the GHRP-2 infusions. Fat mass was measured by anthropometrics (47) .
Study Design
Subjects were studied after an overnight fast on 3 non-consecutive days separated by at least a week. The same study design as previously described (10) , was used in this study. GHRP-2 (0.1 μg/kg per hour), GHRP-2 (1 μg/kg per hour), or placebo (PLAC) was administered in a randomized, double-blind fashion for the entire duration of the experiment (including meal time) using a subcutaneous catheter attached to a pump (MiniMed 508; Medtronic Diabetes, Northridge, CA). Blood was collected for subsequent hormone measurement through an intravenous catheter placed in the forearm, sampled every 30 minutes until the beginning of the meal. The buffet meal included several choices of food served in excess to accommodate a large range of appetite. While eating in the General Clinical Research Center laboratory, the subjects were observed with a camera to ensure their safety and that they did not dispose of the food in any way other than eating. A fixed, standard test breakfast was given 120 minutes after the beginning of the infusion, and the ad libitum lunch was offered at 240 minutes. The breakfast consisted of 1.5 English muffins, 5 grams of butter, and 125 mL of apple juice (1254 kJ, 65% carbohydrates, 4% protein, 31% fat). Before the buffet lunch, subjects listened to taped instructions to "eat as much as they wanted." The items served during the buffet lunch were pasta, bread rolls, peas and carrots, chocolate chip cookies, apple sauce, breaded chicken fillets, and water. Food was weighed before and after the meal, and the caloric intake was calculated. After the meal, the infusion was stopped. Visual analog scales (VASs; from 0, not at all to 150 mm, extremely) to assess hunger, desire to eat, and fullness were administered before starting the infusion, before and after breakfast, and before and after completion of the lunch meal. The positions of the marks on the 150-mm scale were measured in millimeters by a blinded investigator.
Assays
Serum GH concentrations were measured in duplicate by a radioisotopic kit for quantitative determination of hGH from Nichols Institute Diagnostic (San Juan, CA). The assay sensitivity was 0.2 μg/L, and the median intra-and inter-assay coefficients of variation were 2.9% and 7.5%, respectively. Serum cortisol levels were measured by radio-immunoassay (kit from DSL, Webster, TX). The assay sensitivity was 0.11 ng/dL. The median intra-and inter-assay variations were 3.8% and 5.9%, respectively. Hormonal results are incomplete; therefore, data from 14 subjects are reported for GH and from 17 subjects for cortisol.
Statistical Methods
An appetite score was calculated as hunger + (150 mm − fullness) + prospective consumption (48) . General linear model for repeated measure was used to test the effect of treatment [GHRP-2 low dose (LD), GHRP-2 high dose (HD), and PLAC] on FI, with gender and BMI as between-subjects factors. Comparison between groups (lean/obese, men/women) was done by independent Student's t tests. Hormonal response was assessed as area under the curve as measured by the trapezoidal method. A p value of 0.05 was used for level of significance. Data are mean ± standard error unless otherwise stated. SPSS/PC statistical program (version 11.5 for Windows; SPSS, Inc., Chicago, IL) was used for statistical analysis.
Results
FI
GHRP-2 infusion significantly increased FI (n = 19) in a dose-dependent manner by 10.2 ± 3.9% at LD (1422 ± 142 kcal, p = 0.011) and by 33.5 ± 5.8% at HD (1684 ± 158 kcal, p = 0.000) compared with PLAC (1297 ± 133 kcal) ( Figure 1B) . Overall, there was no effect of obesity status on FI stimulation by GHRP-2.
When the data from the lean subjects were analyzed separately, GHRP-2 did not increase FI at LD (p = 0.194) but did at HD by 34.2 ± 8.3% (p = 0.001) vs. PLAC. There was a gender effect in the response to GHRP-2 in the lean group, with a treatment-by-gender interaction at LD (p = 0.016) but not HD. The three lean women were non-responders at LD ( Figure 1A) . When the data from the lean men were analyzed separately, GHRP-2 increased FI both at LD by 10.6 ± 2.9% (p = 0.022) and at HD by 26.1 ± 6.6% (p = 0.009) vs. PLAC. In obese subjects, GHRP-2 increased FI in a dose-dependent manner by 18.3 ± 5.3% (p = 0.039) at LD and by 32.8 ± 8.7% (p = 0.005) at HD compared with PLAC.
Macronutrient Intake
Obese subjects ate more fat at each meal than the lean (46.8% vs. 41.3%, p = 0.024 in the PLAC condition). In the lean group, there was no gender difference in the macronutrient composition of meals. Macronutrient intake was not different between conditions (GHRP-2 at 2 doses and placebo). The absence of effect of GHRP-2 on the macronutrient composition of the meals was not affected by gender or BMI.
Appetite and Hunger Rating by VASs
Lean and obese subjects did not differ in terms of hunger feelings, fullness, desire to eat, or appetite score at baseline before the infusion started. With HD, subjects reported more hunger after the breakfast preload (p = 0.034) and had greater appetite score (p = 0.002) before lunch compared with PLAC. Similarly, GHRP-2 HD increased the desire to eat a meal after breakfast (p = 0.000) and before lunch (p = 0.012) and the desire to eat a favorite food after breakfast (p = 0.031) and before lunch (p = 0.018), compared with PLAC. Subjects were less full before lunch (p = 0.023) with GHRP-2 HD vs. PLAC. However, all subjects experienced the same level of fullness after the buffet lunch. There was no gender or obesity effect for any of the results obtained with VAS rating. GHRP-2 at LD had no effect on any VAS compared with PLAC.
Hormonal Data
Levels of hGH increased significantly and dose dependently during the GHRP-2 infusions, at LD (680 ± 160 μg/L per time, p = 0.013) and HD (4955 ± 664 μg/L per time, p = 0.000), compared with PLAC (236 ± 76 μg/L per time). The effect of GHRP-2 on hGH was different between LD and HD (p = 0.000), and between LD and PLAC (p = 0.011) (Figure 2 ). The maximum serum levels of hGH after GHRP-2 were 37.9 ± 5.9 μg/L for lean men and 28.4 ± 6.2 μg/L for obese women. This was not statistically different. Serum cortisol levels (cortisol area under the curve) increased significantly with GHRP-2 at HD compared with PLAC (2569 ± 153 vs. 1591 ± 123 ng/dL per time, p = 0.000) but not at LD (p = 0.193). There was no gender and/or obesity effect on hGH or cortisol changes with GHRP-2. There was a negative correlation between fasting leptin levels and GH response to HD GHRP-2 (r 2 = 0.673, p = 0.006) but no correlation between fasting insulin and/or leptin and FI response to GHRP-2.
Discussion
The administration of ghrelin stimulates FI (5) and adiposity (4, 5) in rodents and FI in human lean (6) and obese (9) subjects. The ghrelin analog GHRP-2, similarly to ghrelin, stimulates FI in lean men (10) . In this study, GHRP-2 increased FI and GH release in obese individuals. Obese individuals have lower basal and postprandial circulating total ghrelin levels (43, 44) . Lower total serum ghrelin levels in obese patients increase after diet-induced weight loss (49) but not after gastric bypass surgery (40) . This latter fact (50,51) remains controversial (52) (53) (54) . The dysregulation of the ghrelin system could play a part in the pathogenesis of the energy imbalance of obesity; thus, we speculated that the FI response of obese individuals to GHRP-2 could be different than their lean counterparts. Surprisingly, and contrary to our hypothesis, our data show that GHRP-2 administration increases FI in obese women. This is in agreement with recently published data from Druce et al. (9), in which the administration of HD ghrelin stimulated FI in both obese and lean individuals. The magnitude of the ad libitum FI response to GHRP-2 was similar in obese and lean individuals. These results differ from the data obtained with ghrelin in which obese subjects had a greater response than lean subjects at the HD (9). These study discrepancies could be attributed to a difference in the compound, effective dose, and/or protocol design, the last because GHRP-2 was infused for 240 minutes whereas ghrelin was infused for 75 minutes (9) . In addition, it is possible that partial desensitization of the GHRP-2 effect on FI occurred. The redundancies of the physiological regulators of FI are multiple, but the singular role of ghrelin in this regulation merits emphasis because so far it is the only known peripheral hormone that increases FI in humans.
A second aim of our study was to test whether the effect of GHRP-2 on FI was dose dependent. The effect of GHRP-2 on FI occurs at 1 μg/kg per minute, a dose that pharmacologically stimulates hGH and cortisol, whereas at the lower dose of 0.1 μg/kg per minute, these hormonal changes are minimal and are within the physiological range (hGH) or without any hormonal changes (cortisol). GHRP-2 has been shown to increase GH secretion dose dependently (55) . Our data now demonstrate that the GHRP-2 effect on FI is also dose dependent. A smaller but statistically significant stimulation of FI at LD in lean men and obese women (0.1 μg/kg per minute) is a key finding. With the administration of LD GHRP-2, there are minimal or no detectable hormonal changes of GH and cortisol. This supports a dissociation between the FI and GH secretory effect of GHRP-2. Previous animal data have shown that the effect of ghrelin/ GHRP-2 on FI can be dissociated from its hormonal effects (4) , and the effect is, in part (56) (57) (58) , mediated by the neuropeptide Y/Agouti gene-related protein neurons (59) and the melanocortin system in the hypothalamic arcuate nucleus (60, 61) .
Our data reveal that lean women do not have increased FI at the LD infusion of GHRP-2. The small number of lean women in this study does not allow us to comment on these results. Moreover, the absence of men in the obese group prevents any comments on gender/dose interaction. Future studies will address the possible role of gender in the GHRP-2/ghrelin effect on FI.
Data suggest that circulating total ghrelin could be implicated in meal-to-meal regulation. Total ghrelin levels increase in anticipation of a meal (16) and are suppressed by food ingestion (16, 17) . Postprandial suppression of total ghrelin levels is impaired both in obese (43) and anorectic (31) human subjects. The potential mechanisms by which serum ghrelin levels are suppressed after a meal are multiple. The role of macronutrients is apparent in well-controlled rat studies (18) . Although debated (17) , the role of meal-related insulin excursion is possible (27, 62) . Recently, fat digestion (63) was shown to be required, and the role of other gut hormones such as GLP-1 and somatostatin was postulated (28) .
Although the mechanism is not entirely elucidated, the intake of macronutrients seems to play a role in the meal-to-meal regulation of ghrelin secretion. Whether ghrelin/GHRP-2 influences macronutrient choice and intake has been considered. If ghrelin administration stimulates macronutrient intake differentially, a possible regulatory loop system may exist. However, GHRP-2 had no effect on macronutrient dietary choices in our first study in lean individuals (10) or in this study in obese individuals. Similarly, studies by Druce et al. (9) showed that ghrelin administration to humans did not show any effect on macronutrient dietary composition. In our study, obese women ingested more fat than lean subjects at baseline, and this difference was not altered with GHRP-2. Therefore, GHRP-2, like ghrelin, stimulates greater intake of calories but does not preferentially influence types of dietary macronutrient.
There were no significant changes of any of the VAS scores at LD GHRP-2, and yet the FI was significantly greater with GHRP-2 than PLAC. It is possible that the VAS tools we used were insufficiently sensitive to detect changes in perception of fullness and hunger at LD GHRP-2. With GHRP-2 HD, all subjects reported similar levels of hunger and fullness. Gender and BMI had no particular effect on feeling of appetite or fullness. Particularly, the level of fullness after the ad libitum meal was identical between lean and obese, although obese individuals have been shown to have a decreased postprandial sensation of fullness (64) .
The sensitivity effect of GHRP-2 on hGH release was dose dependent, both in lean and in obese subjects, as previously shown (55) . This is contrary to other studies that have shown an impairment of the hGH response to HD ghrelin administration in obese individuals (9, 63) . GH changes with GHRP-2 were not significantly different between lean and obese subjects. Also, in other studies (9, 63) , the older age of the obese subjects could explain a smaller hGH response to ghrelin. In our study, subjects from the lean and obese groups were of a similar young age. Other relevant experimental differences compared with previous studies include different agents, dosages, and, in particular, mode of administration, i.e., subcutaneous infusion in present study vs. intravenous bolus administration in other studies (9) . GHRP-2, like ghrelin (3), stimulates the adrenocorticotropin/cortisol axis, as demonstrated by an increase of serum cortisol levels with HD GHRP-2. Although glucocorticoids have been implicated in FI regulation (65) , it is unlikely that the GHRP-2 effect on FI is mediated by the rise in cortisol because LD GHRP-2 stimulates FI without significant changes of serum cortisol levels.
The GH response to GHRP-2 is inversely correlated to leptin levels. It is probable that the greater the obesity, the higher the circulating leptin and the lower the GHRP-2 GH response. However, this correlation probably does not imply that leptin inhibits the GHRP-2 GH response. Indeed, our data on FI indicates that obese patients are highly sensitive to GHRP-2. Elevated leptin levels do not inhibit the GHRP-2/ghrelin FI response. Moreover, the effect of GHRP-2 on FI is unlikely to be mediated by leptin because the infusion of GHRP-2 at LD and HD does not modify leptin levels (data not shown).
In summary, these data confirm that peripheral subcutaneous infusion of GHRP-2 potently stimulates short-term FI in healthy human lean and obese subjects. This effect is dosedependent and of similar magnitude in obese women and lean men; effects in obese men are yet to be determined. These results further support a role for peripheral circulating ghrelin in the control of FI in humans. So far, these limited data do not support a dysregulation of the ghrelin system in obese individuals. Additional studies are needed to investigate lean-obese differences as a function of age, gender, duration, severity, and stage of obesity, as well as many other factors known to be involved in the regulation of FI. Whether the acute effect of ghrelin/GHRP-2 on FI persists with chronic administration will determine possible clinical uses in malnutrition. Serum GH levels over time (n = 14).
